

ANALYSIS OF HISTOLOGICAL FEATURES PREDICTING THE RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS

Makoto Ooi

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

In a retrospective study of 42 ulcerative colitis patients, higher CD4+ cell infiltration in colonic mucosa before vedolizumab induction was associated with clinical remission at week 22.

KEY POINTS

- Among 42 patients with moderate-to-severe UC treated with vedolizumab, 40.5% achieved clinical remission at week 22.
- Significantly more CD4+ cells were found in colonic mucosal tissues of patients who achieved remission compared to those who did not (odds ratio 1.44, $P=0.014$).
- CD68-positive and CD45-positive areas in the colonic mucosa did not differ significantly between patients with and without remission.
- Concomitant use of corticosteroids ($OR=0.11$, $P=0.008$) and high Mayo scores ($OR=0.50$, $P=0.009$) were negatively associated with vedolizumab response.
- The authors suggest that histological evaluation for CD4+ cell infiltration may help identify UC patients who could benefit from vedolizumab treatment.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflifx.eu/search/d/71aaa512-743b-11ee-8d13-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.